Physician profile
Mandy L Ward
NPI 1871775825
$2,289.42
in general payments reported to CMS, 2019-2025
23 companies · $486 in 2025
The $486 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $76.15 · 2021: $276 · 2022: $396 · 2023: $247 · 2024: $418 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $405.11 | 2019-2025 | Precision7, Hydrus Microstent, Precision 1 |
| Bausch & Lomb Americas INC. | $349.38 | 2022-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $277.87 | 2019-2025 | Acuvue |
| Coopervision INC. | $189.86 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $145.53 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $138.53 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $128.52 | 2020-2022 | |
| Allergan, INC. | $123.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.95 | 2019-2022 | |
| Abbvie INC. | $90.59 | 2022-2025 | |
| Astellas Pharma US INC | $68.15 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $53.86 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.72 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $41.30 | 2019 | |
| Amgen INC. | $26.10 | 2025 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.56 | 2025 | Iyuzeh |
| Omeros Corporation | $15.37 | 2019 | |
| Biotissue Holdings INC. | $14.45 | 2025 | |
| Glaukos Corporation | $14.27 | 2019 | |
| New World Medical,INC. | $12.09 | 2023 | |
| Synergeyes, INC. | $12.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.99 | 2019 | |
| Shire North American Group INC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.